Thromboxane modulating agents. 2. Thromboxane receptor antagonists derived from the thromboxane synthase inhibitor dazmegrel

Bioorganic and Medicinal Chemistry Letters

Volumn 6, Issue 14, 1996, Pages 1691-1696

  Dickinson, Roger P ^a   Dack, Kevin N ^a   Steele, John ^a   Tute, Michael S ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; DAZMEGREL; THROMBOXANE RECEPTOR; THROMBOXANE RECEPTOR BLOCKING AGENT; THROMBOXANE SYNTHASE;

ANIMAL TISSUE; AORTA; ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; NONHUMAN; NORMAL HUMAN; RAT; REACTION ANALYSIS; SMOOTH MUSCLE CONTRACTION; STRUCTURE ACTIVITY RELATION; THROMBOCYTE;

ANIMALIA;

EID: 0030598668     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0960-894X(96)00299-5     Document Type: Article

References (25)

1. (1) Cross, P.E.; Dickinson, R.P. Annual Reports in Medicinal Chemistry Volume 22; Bailey, D.M., Ed.; Academic Press, Inc.; Orlando, 1987; pp 95-105.
2. (2) Collington, E.W.; Finch, H. Thromboxane Synthetase Inhibitors and Receptor Antagonists. Annual Reports in Medicinal Chemistry Volume 25; Bristol, J.A., Ed.; Academic Press, Inc.; San Diego, 1990; pp 99-108.
3. (3) Cozzi, P.; Salvati, P. Curr. Opinion. Therapeutic Patents 1991, 1343-1373.
4. (4) Nijkamp, F.P.; Moncada, S.; White, H.L.; Vane, J.R. Eur. J. Pharmacol. 1977, 44, 79-186.
5. (5) Needleman, P.; Wyche, A.; Raz, A. J. Clin. Invest. 1979, 63, 345-349.
6. (6) Cross, P.E.; Dickinson, R.P.; Parry, M.J.; Randall, M.J. J. Med. Chem. 1986, 29, 342-346.
7. (7) Fischer, S.: Struppler, M.; Böhlig, B.; Bernutz, C.; Wober, W.; Weber, P.C. Circulation 1983, 68, 821-826.
8. (8) Lorenz, R.L.; Fischer, S.; Wober, W.; Wagner, H.A.; Weber, P.C. Biochem. Pharmacol. 1986, 35, 761-766.
9. (9) FitzGerald, G.A.; Reilly, I.A.G.; Pedersen, A.K. Circulation 1985, 72, 1194-1201.
10. (10) Hall, S.E. Med. Res. Rev. 1991, 11, 503-579.
11. (11) Misra, R.N. Exp. Opin. Invest. Drugs 1994, 3, 469-480.
12. (12) Bhagwat, S.S. Drugs of the Future 1994, 79, 765-777.
13. (13) Dickinson, R.P.; Dack, K.N.; Steele, J. Bioorg. Med. Chem. Lett. 1995, 5, 3017-3022.
14. (14) Cooper, D.G.; Gribble, A.D. European Patent 0365183, 1990.
15. (15) De Graw, J.L; Brown, V.H.; Skinner, W.A. J. Med. Chem. 1966, 9, 140-142.
16. (16) Noland, W.E.; Rush, K.B. J. Org. Chem. 1963, 28, 2921-2922.
17. (17) Cross, P.E.; Dickinson, R.P.; Parry, M.J.; Randall, M.J. J. Med. Chem. 1985, 28, 1427-1432.
18. (18) Ladouceur, G.; Mais, D.E.; Jakubowski, J.A.; Utterback, B.G.; Robertson, D.W. Bioorg. Med. Chem. Lett. 1991, 1, 173-178.
19. (19) Ezumi, K.; Yamakawa, M.; Narisada, M. J. Med. Chem. 1990, 33, 1117-1122.
20. (20) Cozzi, P.; Giordani, A.; Menichincheri, M.; Pillan, A.; Pinciroli, V.; Rossi, A.; Tonani, R.; Volpi, D.; Tamburin, M.; Ferrario, R.; Fusar, D.; Salvati, P. J. Med. Chem. 1994, 37, 3588-3604.
21. (21) Jin, B.; Hopfinger, A.J. J. Chem. Inf. Comput. Sci. 1994, 34, 1014-1021.
22. (22) Detailed X-ray crystallographic data for 3b have been deposited at the Cambridge Crystallographic Data Centre.
23. (23) The program SYBYL, available from Tripos Associates Inc., St. Louis, MO, was used in conjunction with the MAXIMIN 2 force field.
24. (24) Corey, E.J.; Su, W-g. Tetrahedron Lett. 1990, 31, 2677-2680.
25. (25) Motoyama, Y.; Seki, J.; Namikawa, Y.; Oka, Y.; Sakata, Y.; Yoshida, K. Thromb. Haemostasis 1989, 62, 1297.